Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT04820023
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
- NCT04820023 ↗
- Terminated
- Bridge Biotherapeutics, Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT04820023 (BBT-176 in advanced NSCLC with progression after EGFR TKI treatment) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04820023 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BBT-176 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Agent
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- NSCLC
- Interventions
- BBT-176, QD; BBT-176, BID
- Arms
- 20mg QD · Experimental
- 80mg QD · Experimental
- 160mg QD · Experimental
- 320mg QD · Experimental
- 480mg QD · Experimental
- 600mg QD · Experimental
- 160mg, BID · Experimental
- 200mg, BID · Experimental
- 240mg, BID · Experimental
- Enrollment
- 45
- Primary outcomes
- (Part 1) Incidence of Adverse Events and Clinical Laboratory Abnormalities Defined as Dose-limiting Toxicities (DLTs)
- (Part 2) Objective Response Rate (ORR)
- Sponsor
- Bridge Biotherapeutics, Inc.
- Start
- Apr 2, 2021
- Primary completion
- Nov 29, 2023
- Results posted
- Yes
- Registry record
- NCT04820023 · updated Jun 6, 2025
Publications
linked from the registry- Lim SM, Fujino T, Kim C, Lee G, Lee YH, Kim DW, Ahn JS, Mitsudomi T, Jin T, Lee SY. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 Aug 15;29(16):3004-3016. doi: 10.1158/1078-0432.CCR-22-3901. PubMed 37249619